Published in final edited form as:

Exp Biol Med (Maywood). 2013 March 1; 238(3): 276–284. doi:10.1177/1535370213482442.

Directed neural differentiation of induced pluripotent stem cells from nonhuman primates

Steven L. Farnsworth¹, Zhifang Qiu¹, Anuja Mishra, and Peter J. Hornsby

Geriatric Research Education and Clinical Center, South Texas Veterans Health Care System, San Antonio, TX 78229; and Department of Physiology and Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center, San Antonio, TX 78245

Abstract

Induced pluripotent stem cells (iPS cells) are important for the future development of regenerative medicine involving autologous cell therapy. Before autologous cell therapy can be applied to human patients, suitable animal models must be developed, and in this context nonhuman primate models are critical. We previously characterized several lines of marmoset iPS cells derived from newborn skin fibroblasts. In the present studies, we explored methods for the directed differentiation of marmoset iPS cells in the neuroectodermal lineage. In this process we used an iterative process in which combinations of small molecules and protein factors were tested for their effects on mRNA levels of genes that are markers for the neuroectodermal lineage. This iterative process identified combinations of chemicals/factors that substantially improved the degree of marker gene expression over the initially tested combinations. This approach should be generally valuable in the directed differentiation of pluripotent cells for experimental cell therapy.

Keywords

Induced pluripotent stem cells; nonhuman primates; differentiation; cell therapy

Introduction

Nonhuman primate iPS cells in regenerative medicine

Induced pluripotent stem cells (iPS cells) are believed to represent a major approach to the future development of regenerative medicine (1). It is widely thought that a form of autologous cell therapy will be possible, in which iPS cells would be derived from the patient's cells, in order to provide a source for cells that could be transplanted back to the patient to restore function to the heart, central nervous system, hematopoietic system, or other organs that are affected by disease or aging. Following the discovery of iPS cells, it was almost immediately realized that this discovery opened the way to autologous cell therapy. A review in 2007 stated: "If this method can be translated to humans, patient-specific stem cells could be made without the use of donated eggs or embryos" (2). It is assumed that if the cells are accepted as "self" then they would represent the best possible functional outcome of a transplant: cells that function in their natural environment, without

Author for correspondence: Peter J. Hornsby, Ph.D., University of Texas Health Science Center, 15355 Lambda Drive, San Antonio, TX 78245, hornsby@uthscsa.edu.

¹These authors contributed equally to this work

Statement of Author Contributions

All individuals who made contributions to this study are included as authors.

Conflict of interest and other declarations:

There are no conflicts of interest to declare.

eliciting chronic immune or inflammatory reactions, and without the problems that would result from the use of immunosuppressive drugs.

Before it would be possible to consider applying autologous cell therapy to human patients, the properties of iPS cells must be thoroughly explored in suitable animal models, in order to make sure that autologous cell therapy is both safe and effective. It has been generally recognized that clinically relevant experiments should be performed in a nonhuman primate (NHP) rather than a rodent. NHPs are thought to be ideal for such preclinical trials because of their relatedness to humans and their similar physiology, particularly with respect to the central nervous system. Long-term studies of transplanted cell function (3 years) will be possible in NHPs, but are impossible in rodents. Thus there is a clear path from basic to translational studies in iPS cell-based regenerative medicine in NHPs. Of the various NHPs that could be used, the common marmoset (*Callithrix jacchus*) has several advantages, as previously described (3). For this reason, we previously characterized several lines of marmoset iPS cells derived from newborn skin fibroblasts (4).

Directed differentiation of pluripotent stem cells

A universal need in regenerative medicine is the large-scale production of differentiated cells from a pluripotent cell source, either embryonic stem cells or iPS cells. The requirements for such cells are that they should be sufficiently differentiated to accomplish the goals of cell therapy, while not being too differentiated as to impair successful transplantation. In particular, teratoma-forming undifferentiated pluripotent cells must be eliminated prior to cell therapy being initiated. Protocols for differentiation in a variety of desired lineages have been evolving rapidly. Early protocols used mostly undefined materials and mixtures, while more recent emphasis has been on a rational approach involving interventions in cellular pathways known to be or hypothesized to be involved in differentiation, using chemicals/drugs or defined protein factors (5, 6) (Fig. 1). These protocols have lowered the time taken to form a differentiated cell population from several weeks to much shorter periods of 10 – 20 days.

A significant advance in the field of neural differentiation from pluripotent cells was the introduction of the concept of dual SMAD inhibition (7). Initially this was accomplished by the combination of noggin and SB431542, while later versions substituted chemical inhibitors such as dorsomorphin for the more expensive noggin (8, 9). This forms one example of how, over the last few years, an armamentarium of small-molecule agents has been developed that are available for differentiation protocols (5, 6). The need now is to be able to rationally combine selected compounds in protocols that take advantage of results of prior studies and of increasing knowledge of the pathways that have been identified as being involved. In many ways the experimenter attempts to mimic the multiple stages of actual embryonic development in the dish (Fig. 1). This also requires the identification of suitable molecular markers needed for each developmental stage. Furthermore, the adaptation of protocols across species (for example, from humans to NHPs) requires adjustments in concentrations of inducing molecules and in the timing of their addition.

Optimizing differentiation protocols

As protocols for directed differentiation of pluripotent cells have proliferated, the number of factors available to the experimenter for testing has greatly increased (5). Each factor should be used at an optimal concentration. Therefore, the potential number of combinations of factors and concentrations that might be tested in differentiation protocols can become very large (10). As the list of molecules useful to control stem cell fate decision gets longer, so does the list of factor interactions that need to be understood (11). Moreover, protocols can be very sensitive to small changes in concentrations of inducing factors. For example, with

reference to a protocol for oligodendrocyte differentiation (12): “The most surprising aspect is how sensitive the cells are to the concentration of the reagents... Very small changes give you precise results” (13). Systematic approaches to handling large numbers of factors and concentrations are needed, with the aim of significantly reducing the number of experiments required to arrive at meaningful results (10, 14). Instead of conducting experiments in a traditional way, where factors are varied one by one and independently, an experimental approach in which multiple factors are changed simultaneously in a controlled manner becomes very attractive. Combinations should be tested simultaneously, not sequentially, because of possible interactions among the factors, which may be both predicted and unexpected. Several examples of ways factors can interact are described by Audet (11). For example, one factor might induce the receptor for a second factor. In that case, testing the second factor in the absence of the first could result in a lack of a response. On the other hand, iterative testing of the two factors together can yield an optimal combination that maximizes the induction of the receptor by the first factor and the resultant response to the second factor. Methodologies involving simultaneous testing and iterative optimization have been widely adopted in bioprocess optimization, and to some extent in drug screening, but far less frequently in stem cell research (14).

In an example of the use of iterative approach to searching for an optimal combination of multiple factors and multiple concentrations, Tsutsui et al. (15) studied 5 factors implicated in maintaining pluripotency and avoiding unwanted differentiation of human embryonic stem cells. Starting with concentrations of the 5 factors thought to be useful based on prior literature, in each round of experiments they systematically varied the concentrations of each of the 5 factors and assessed the resultant level of pluripotency by OCT4 expression and alkaline phosphatase staining. Identification of an effective small molecule combination for maintenance of pluripotency required testing 192 combinations in 6 rounds; if they had used a “brute-force” approach it would have been necessary to test 7,776 possible combinations (15).

In adapting the approach of Tsutsui et al., we opted to employ a simpler “hill-climbing” algorithm for optimizing chemical/factor combinations in differentiation protocols. We assume that the degree of differentiation of the cells following combination treatments is evaluable as a single value - a theoretical concept, but useful for the purpose of illustration. The metaphor of hill climbing refers to the concept that the values representing the outcomes of all possible chemical/factor combinations can be plotted as a 3-dimensional surface, i.e. a fitness landscape. The highest point in the landscape represents the optimal combination for the measures of differentiation being used (Fig. 2).

Hill climbing is a technique that is applicable to a wide variety of situations where optimization is desired. The “hill climb” begins with any (suboptimal) solution to the problem and then iteratively improves the solution until some condition is maximized (the top of the hill is reached). Hill climbing is an example of an informed search method because it uses information about the search space to search in a reasonably efficient manner (16). Using the metaphor of climbing a real hill in fog, the algorithm can be stated as “check the height 1 foot away from your current location in each direction; move to the point that is highest; then repeat the algorithm. If all directions lead to a point lower than the current position it is assumed that the summit has been reached.” Hill climbing algorithms can run afoul of foothills, plateaus and ridges in the fitness landscape (16). For this reason more complex algorithms may be preferred, which use strategies to avoid landscape features that represent local maxima as opposed to a global maximum (10). Where prior knowledge of the nature of the landscape exists, more complex approaches might be necessary; for example, to determine drug combinations that inhibit vesicular stomatitis virus infection and combinations of cytokines that regulate NF- κ B (17). In a second example where hill

climbing was not thought to be suitable as an algorithm, an iterative approach was used to select an optimal combination from among 82,950 possible combinations by exploring 0.5% of the space in experiments to optimize the formulation of amphotericin B in lipids (18). On the other hand, hill climbing was shown to be applicable to a search for effective combinations of 19 anti-cancer drugs (19). As these authors point out, to be useful, the algorithm needs only to find combinations that have fitness levels that are “good enough” with respect to the aim of the experiments, and to be more efficient than a random screen. In the absence of examples to the contrary, it is simpler to begin with the assumption in differentiation protocols that there is a single global optimum for drug/factor combinations, rather than any more complex situation. In such a case, hill climbing is the fastest method to determine the optimal combination (Fig. 2).

Methods

Marmoset induced pluripotent stem cells

A line of marmoset iPS cells was grown as previously described (4). At the beginning of the differentiation protocols, cells were removed from the dish with Accutase (20). Cells were then transferred into different differentiation media, as described below.

Differentiation Protocol #1

In this protocol, cells were permitted to aggregate into embryoid bodies using 384-well hanging-drop plates (3D Biomatrix, Ann Arbor, MI). Cells were placed in DMEM/F12 medium containing 20% Knockout Serum Replacement (KSR; Invitrogen), 0.32 μ M dorsomorphin HCl (Tocris), 0.32 μ M SB431542 (Selleck), 1 nM all-*trans* retinoic acid (Sigma), 10 μ M Y-27632 (Abcam Biochemicals), 20 ng/ml FGF2 (Stemgent), 25 μ g/ml insulin (bovine, Sigma). Each well of the hanging-drop plate received 3000 cells in 30 μ l of this medium. Plates were placed in a humidified incubator at 37.5 °C for 72 hours. Following this incubation period, the resultant early embryoid bodies were collected from the plate. They were then dissociated to single cells by incubation in 1 ml 0.25% trypsin-EDTA for 30 min at room temperature. Cells were transferred into DMEM/F12 medium containing 20% KSR, 2% B27 supplement (Invitrogen), 15 μ g/ml transferrin (human, Sigma), and various concentrations of retinoic acid, SB431542, dorsomorphin, FGF2, and SAG (Sonic hedgehog agonist; EMD Chemicals). Cells in these various drug/factor combinations were plated on Matrigel-coated 35-mm plates at 10,000 cells/cm² and were maintained in the same media for 72 hours. Following this period, cells were harvested to make RNA (RNA-Bee, Tel-Test Inc.).

Differentiation Protocol #2

In this protocol, cells were permitted to aggregate in U-bottom 96-well plates (Greiner BioOne #650161), previously treated for 24 hours with 10% (w/v) Pluronic F68 (Sigma) which prevents attachment of the cells to the wells (21). Marmoset iPS cells were dissociated with Accutase. Each well received 3000 cells in 150 μ l differentiation medium. Differentiation medium comprised DMEM/F12 with 20% KSR, 10 μ M Y-27632 and 1 nM all-*trans* retinoic acid, together with variable concentrations of DMH1 (dorsomorphin analogue, Millipore), SB431542 (Selleck), BIO ((2'Z,3'E)-6-bromoindirubin-3'-oxime; Enzo), and PD0325901 (Selleck). On days 2 and 4, each well received an additional 75 μ l of medium containing the same combination of factors as originally added on day 0. After 6 days, cells were harvested to make RNA. Levels of mRNAs were determined using standard qPCR techniques and are reported as cycles versus β -actin, using marmoset gene-specific primers.

Results

Small molecule/protein factor combinations for neuroectodermal differentiation of marmoset iPS cells

We based our search for optimal differentiation cocktails on the work of Tsutsui et al. (15). The approach is illustrated in Fig. 2. As in Tsutsui et al., we started with level “3” of each factor (Table 1) and then varied the concentrations systematically. The starting concentration “3” is a concentration based on values shown to be effective in the literature, although those experiments typically did not systematically investigate different concentrations. The other levels (1, 2, 4, 5, etc.) are based on the concentration “3” by decreasing or increasing the concentration by a factor of square root of 10, except for retinoic acid, which was increased or decreased by a factor of 10. Therefore, the combination 33333 for protocol #1 comprises 0.1 μ M retinoic acid, 1 μ M SB431542, 1 μ M dorsomorphin, 20 ng/ml FGF2, and 1 μ M SAG (Sonic hedgehog agonist). We systematically varied each factor by one step up and down in each iteration; therefore with combinations of 5 molecules we used 11 combinations in each round.

In protocol #1 we tested the combinations of 5 factors (Table 1) beginning with concentrations (“3”) that were previously determined to be useful in neuroectodermal differentiation in the literature. At each round, each of the 5 factors was varied by one increased step and one decreased step (Fig. 2). At each round, cells were harvested for RNA preparation followed by qPCR of a set of genes that were selected based on prior knowledge that they may be informative in differentiation in this lineage. Based on an assessment of the levels of mRNA for these genes a “winner” combination of the round was chosen. In these experiments we assessed “winners” by an overall assessment of the set of genes. In a future expansion of this work, this could potentially be done mathematically; however, at the present stage of development of this approach we do not have sufficient information to formulate a purely mathematical method for “winner” selection.

We tested two different protocols for assessing combinations of drugs and protein factors in differentiation. Both protocols are based on schemes for the differentiation of pluripotent cells in the neuroectodermal lineage (22). Both are also based on the concept that the initiation of differentiation in this lineage is enhanced by formation of a three-dimensional structure. These aggregates, if allowed to remain as 3-dimensional structures, will eventually form mature embryoid bodies (EBs). The two protocols differ in the following respect. In the first, a mass production of early EBs under standardized conditions for 3 days was followed by dissociation of the cells and individual treatments of the plated cells. Thus, no variations in treatment occurred over the first 3 days, but variations occurred in the 3 days the cells spent as monolayer-plated cells. The mass production of the EBs, using commercially available 384-well hanging-drop plates, is efficient, but is not convenient for assessing the effects of varying treatments during the 3 days of hanging-drop EB formation, as opposed to the subsequent plated cell step (total 6 days protocol). In protocol #2, variations in the treatments during EB formation are possible because the cells were allowed to form EBs in 96-well plates. In this case the format is adaptable to variations in the treatment of the cells during EB formation. Medium containing fresh additives was re-added to the wells at intervals. In this case the same additions were made over the period of the experiment, but this could be varied. Re-addition is not possible using hanging-drop plates, as the medium for the drops cannot be changed during EB formation and the time is limited to 3 days because of concerns about excessive evaporation over longer time periods.

Protocol #1: Hanging-drop plate protocol

In the hanging-drop protocol, we screened 5 small molecules/factors for their effects on expression of 10 genes (Fig. 4). These genes are involved in neuroectodermal differentiation generally, and more specifically in motor neuron differentiation (23, 24). For most of the genes studied, there was a rapid increase in the extent of increase in mRNA levels over 2 rounds. Most of the improvement was in the range of 2^3 to 2^4 , i.e. 8-fold to 16-fold increases over the level of induction observed with the starting combination ("3333"); however, some exceeded this improvement (e.g. *SOX10*, which showed an overall improvement in induction of 2^6 , i.e. 64-fold, and *OLIG2*, which showed an overall improvement in induction of 2^5 , i.e. 32-fold).

Protocol #2: 96-well plate protocol

The results of the approach in the 96-well protocol (Fig. 5) showed generally small improvements over the starting combination ("3333"; Table 1). "Winner" combinations were much less obvious than in protocol #1. *MSH* (musashi) mRNA increased by about 3-fold, comparing round 3 versus the starting combination. *NCAD* (N-cadherin) showed a 2-fold improvement. *TFAP2A* was generally unchanged, which appeared to be because this mRNA is not responsive to the combinations of small molecules used in these tests.

Discussion

These studies address the problem of optimizing the differentiation of pluripotent cells for cell therapy, including models of autologous cell therapy in NHPs. While protocols for pluripotent cell differentiation have been evolving rapidly, systematic approaches to optimizing differentiation have so far been uncommon. We propose that systematic approaches, similar to that described here, will be necessary in order to avoid the twin problems of low rates of differentiation into desired lineages and protocols that take very long time periods. In this study we used combinations of molecules (drugs and protein factors) in an iterative scheme, with the aim of improving neuroectodermal differentiation of NHP iPS cells. Our aim was to maximize expression of markers of the neuroectodermal lineage using short (6-day) treatment protocols. For future cell therapy, it is desirable to achieve as much differentiation as possible in the desired lineage using drug/factor treatments, thereby reducing dependence on subsequent processing to isolate specific desired subpopulations of cells. While cell sorting will almost certainly be required for the future use of cells in experimental cell therapy and in human regenerative medicine, the initial approach should be to optimize differentiation using protocols that are rapid, simple, and scalable.

The results of these studies show that the approach is feasible and simple to implement. We used a straightforward algorithm for iterative testing of small molecule/protein factor combinations. The results showed rapid improvements in neuroectodermal gene induction in a 2-stage protocol involving 3 days of EB formation in hanging-drop culture followed by 3 days of drug/factor treatment of the dissociated cells in monolayer culture. The improvement was more modest in a 6-day protocol in which the cells were maintained throughout as EBs in 96-well plates. The rapid improvement in the case of the hanging-drop protocol was mostly the result of the increase in retinoic acid concentrations over the 3 rounds of the experiment. Based on the literature, the initial concentration was set at 100 nM, while 10 μ M eventually proved to be much more effective. The initial concentration has been shown to be optimal in some systems (e.g. 25, 26) while the higher concentration has been used in others (27, 28). Presumably, because 10 μ M is greatly in excess of the physiological concentration of retinoic acid, cross-reaction with another pathway may be involved; further studies are needed to clarify this point. In the case of the 6-day EB protocol, the combination

initially used may already have been close to optimal, thus reducing the chance of finding a more effective combination. Again, further experience with the system is needed to establish whether this is a common occurrence, and additional factors must be tested in both protocols.

Because the process in vitro is intended to recapitulate a series of developmental stages in the embryo, the in vitro process may require multiple stages with changing strategies; both different structures (e.g. monolayers or EBs) and differing combinations of chemicals/factors may be needed at different stages of the process. Iterative approaches to optimization could be used at each stage. Because of the complexity of many differentiation protocols, and because the molecular targets of the drugs/factors used are not always known, it is not yet clear whether a simple “hill climbing” iterative approach to optimizing differentiation will always be appropriate. More complex algorithms might be necessary. This will require enough testing to ensure that the theoretical possibility that the search becomes “stuck” on a local maximum rather than a global maximum is unlikely. However, if practical experience shows that this happens with some frequency, algorithms should be adjusted to avoid this.

Extensions of this approach can be envisioned in which synthetic mRNAs are used in combinations, essentially employing synthetic mRNAs like other drugs and small molecules (29). It was already suggested, in the context of transdifferentiation (reprogramming) protocols using transcription factors, that “a subset of factors may be selected for retesting in the reprogramming assay,” i.e. an iterative approach as employed here (30). By combining optimal small molecules and mRNA treatment, very efficient and rapid differentiation protocols may be feasible for future regenerative medicine studies.

Acknowledgments

All authors participated in the design and interpretation of the studies, analysis of the data, and wording of the manuscript; SLF and QZ conducted the experiments, AM provided excellent assistance with all aspects of the experiments, and PJH was responsible for the overall planning of the experiments and the manuscript.

Financial support

This work was supported by grant I01BX001454 from the Department of Veterans Affairs to PJH, and also by grants from the Ted Nash Long Life Foundation and the Owens Medical Foundation. SLF was supported by an individual fellowship (F30DE022494) and by the COSTAR training grant T32DE014318.

References

1. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007; 131:861–72. [PubMed: 18035408]
2. Rossant J. Stem cells: the magic brew. *Nature*. 2007; 448:260–2. [PubMed: 17637646]
3. Wu Y, Mishra A, Qiu Z, Farnsworth S, Tardif SD, Hornsby PJ. Nonhuman primate induced pluripotent stem cells in regenerative medicine. *Stem Cells Int*. 2012; 2012:767195. [PubMed: 22577396]
4. Wu Y, Zhang Y, Mishra A, Tardif SD, Hornsby PJ. Generation of induced pluripotent stem cells from newborn marmoset skin fibroblasts. *Stem Cell Res*. 2010; 4:180–188. [PubMed: 20363201]
5. Efe JA, Ding S. The evolving biology of small molecules: controlling cell fate and identity. *Philos Trans R Soc Lond B Biol Sci*. 2011; 366:2208–21. [PubMed: 21727126]
6. Zhu S, Wei W, Ding S. Chemical strategies for stem cell biology and regenerative medicine. *Annu Rev Biomed Eng*. 2011; 13:73–90. [PubMed: 21513460]
7. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat Biotech*. 2009; 27:275–280.

8. Zhou J, Su P, Li D, Tsang S, Duan E, Wang F. High-efficiency induction of neural conversion in human ESCs and human induced pluripotent stem cells with a single chemical inhibitor of transforming growth factor beta superfamily receptors. *StemCells*. 2010; 28:1741–1750.
9. Morizane A, Doi D, Kikuchi T, Nishimura K, Takahashi J. Small-molecule inhibitors of bone morphogenic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells. *J Neurosci Res*. 2011; 89:117–26. [PubMed: 21162120]
10. Feala JD, Cortes J, Duxbury PM, Piermarocchi C, McCulloch AD, Paternostro G. Systems approaches and algorithms for discovery of combinatorial therapies. *Wiley Interdiscip Rev Syst Biol Med*. 2010; 2:181–93. [PubMed: 20836021]
11. Audet J. Adventures in time and space: Nonlinearity and complexity of cytokine effects on stem cell fate decisions. *Biotechnol Bioeng*. 2010; 106:173–82. [PubMed: 20198618]
12. Najm FJ, Zaremba A, Caprariello AV, Nayak S, Freundt EC, Scacheri PC, Miller RH, Tesar PJ. Rapid and robust generation of functional oligodendrocyte progenitor cells from epiblast stem cells. *Nat Methods*. 2011; 8:957–62. [PubMed: 21946668]
13. Baker M. Author file: Paul Tesar. *Nat Methods*. 2011; 8:887. [PubMed: 22148152]
14. Ranga A, Lutolf MP. High-throughput approaches for the analysis of extrinsic regulators of stem cell fate. *Curr Opin Cell Biol*. 2012; 24:236–44. [PubMed: 22301436]
15. Tsutsui H, Valamehr B, Hindoyan A, Qiao R, Ding X, Guo S, Witte ON, Liu X, Ho CM, Wu H. An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. *Nat Commun*. 2011; 2:167. [PubMed: 21266967]
16. Coppin, B. *Artificial Intelligence Illuminated*. Sudbury, MA: Jones and Bartlett; 2004.
17. Wong PK, Yu F, Shahangian A, Cheng G, Sun R, Ho CM. Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. *Proc Natl Acad Sci USA*. 2008; 105:5105–10. [PubMed: 18356295]
18. Caschera F, Gazzola G, Bedau MA, Bosch Moreno C, Buchanan A, Cawse J, Packard N, Hanczyc MM. Automated discovery of novel drug formulations using predictive iterated high throughput experimentation. *PLoS One*. 2010; 5:e8546. [PubMed: 20049327]
19. Zinner RG, Barrett BL, Popova E, Damien P, Volgin AY, Gelovani JG, Lotan R, Tran HT, Pisano C, Mills GB, Mao L, Hong WK, Lippman SM, Miller JH. Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. *Mol Cancer Ther*. 2009; 8:521–32. [PubMed: 19276160]
20. Bajpai R, Lesperance J, Kim M, Tersikh AV. Efficient propagation of single cells Accutase-dissociated human embryonic stem cells. *Mol Reprod Dev*. 2008; 75:818–27. [PubMed: 18157870]
21. Wu M-H. Simple poly(dimethylsiloxane) surface modification to control cell adhesion. *Surf Interface Anal*. 2009; 41:11–16.
22. Eiraku M, Watanabe K, Matsuo-Takasaki M, Kawada M, Yonemura S, Matsumura M, Wataya T, Nishiyama A, Muguruma K, Sasai Y. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. *Cell Stem Cell*. 2008; 3:519–32. [PubMed: 18983967]
23. Nizzardo M, Simone C, Falcone M, Locatelli F, Riboldi G, Comi GP, Corti S. Human motor neuron generation from embryonic stem cells and induced pluripotent stem cells. *Cell Mol Life Sci*. 2010; 67:3837–47. [PubMed: 20668908]
24. Lopez-Gonzalez R, Velasco I. Therapeutic potential of motor neurons differentiated from embryonic stem cells and induced pluripotent stem cells. *Arch Med Res*. 2012; 43:1–10. [PubMed: 22293229]
25. Tsuji O, Miura K, Okada Y, Fujiyoshi K, Mukaino M, Nagoshi N, Kitamura K, Kumagai G, Nishino M, Tomisato S, Higashi H, Nagai T, Katoh H, Kohda K, Matsuzaki Y, Yuzaki M, Ikeda E, Toyama Y, Nakamura M, Yamanaka S, Okano H. Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. *Proc Natl Acad Sci USA*. 2010; 107:12704–9. [PubMed: 20615974]
26. Hu BY, Weick JP, Yu J, Ma LX, Zhang XQ, Thomson JA, Zhang SC. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. *Proc Natl Acad Sci USA*. 2010; 107:4335–40. [PubMed: 20160098]

27. Erceg S, Lainez S, Ronaghi M, Stojkovic P, Perez-Arago MA, Moreno-Manzano V, Moreno-Palanques R, Planells-Cases R, Stojkovic M. Differentiation of human embryonic stem cells to regional specific neural precursors in chemically defined medium conditions. PLoS ONE. 2008; 3:e2122. [PubMed: 18461168]
28. Chatzi C, Scott RH, Pu J, Lang B, Nakamoto C, McCaig CD, Shen S. Derivation of homogeneous GABAergic neurons from mouse embryonic stem cells. Exp Neurol. 2009; 217:407–16. [PubMed: 19348800]
29. Ruder WC, Lu T, Collins JJ. Synthetic biology moving into the clinic. Science. 2011; 333:1248–52. [PubMed: 21885773]
30. Cohen DE, Melton D. Turning straw into gold: directing cell fate for regenerative medicine. Nat Rev Genet. 2011; 12:243–52. [PubMed: 21386864]

Fig. 1.

The basic principle underlying protocols that aim for efficient and rational differentiation of pluripotent cells. A typical differentiation protocol goes through multiple stages, attempting to mimic embryonic development by using molecules to stimulate the pathways that are required, while using the same or other molecules to block unwanted differentiation to other pathways at each stage. In this diagram, intermediate cell populations are termed “stem/progenitor cells” although they may not directly correspond to any population of cells found in actual tissues *in vivo*, either in the embryo or the adult. At the end of the process illustrated here the aim is to have a population of cells that are suitable for cell therapy or for other purposes. Diagram adapted from ref. 6.

Fig. 2.

A process for optimizing differentiation protocols that use combinations of multiple small molecule drugs or protein factors. The panel on the left outlines the process by which combinations of chemicals/factors are iteratively tested with respect to a desired outcome, i.e. the level of differentiation as assessed by suitable markers. At each round the outcome is assessed, and a new base combination is selected to begin the new round. The “winner” combination in each round is chosen according to a hill climbing algorithm. This depends on simultaneous, rather than sequential, optimization of the drug combinations. The rationale for simultaneous optimization is illustrated in the image in the upper right panel. Two drugs (X and Y) are depicted that strongly synergize at concentration “3” but less so or not at all at other concentrations. If each drug were tested first in the absence of the other, only weak responses (shown as the elevation at different places on the hill) would be recorded, while testing of the two together can result in a rapid determination of the optimum combination (“hill climbing,” as described in detail in the text). The method is shown in the lower panel on the right. In this case the optimization of 5 drugs used in combination is shown. The first round begins with each drug used at concentration “3” representing a presumably effective concentration previously determined from the literature (see Table 1 for actual examples). Apart from the 33333 combination, 10 other variations are tested in which each drug is varied by increasing the concentration by one step (to level “4”) and by decreasing one step (to level “2”). After the “winner” combination is identified, this combination is used as the base combination in round 2. Rounds may be repeated as necessary until no further improvement in the differentiation is obtained.

Fig. 3.

Representative images of marmoset iPS cells subjected to two different differentiation protocols using chemical/factor combinations. In **A**, a hanging-drop plate in which EBs are formed from dissociated iPS cells is shown (protocol #1). As described in Methods, EBs were collected after 3 days and dissociated for subsequent plating. **A'** shows the appearance of the collected EBs before dissociation. During the subsequent monolayer stage, the cells were treated with small molecule combinations. The cell morphology at the end of the protocol (6 days) is shown above for 11 different combinations (see Table 1). “d0” refers to day 0, the appearance of the marmoset iPS cells in feeder-free conditions before dissociation. In **B**, a 96-well plate is shown in which EBs were formed and simultaneously treated with small molecule combinations for 6 days (protocol #2). The appearance of representative EBs for each combination used is shown at the end of the protocol (6 days).

Fig. 4. Levels of neuroectodermal gene mRNAs resulting from differentiation of marmoset iPS cells via protocol #1. For each gene, the tables list the mRNA levels as measured by qPCR for various chemical/factor combination in each of three rounds. The values in the tables are given as $C_t(\beta\text{-actin}) - C_t(\text{gene})$. The numeric code is explained in the text and is shown in Table 1. The day 0 (d0) mRNA levels, in the undifferentiated cells, are plotted as open squares. The mRNA levels in the cells at 6 days are plotted as open circles, both for the starting combination in each round and for the “winner” combination for that round. For round 1, the open circles show the mRNA levels for the 33333 combination and the “winner” combination, 43333; for round 2, levels for 43333 and the “winner” combination, 53333; for round 3, levels for 53333 and the “winner” combination, 53334.

Fig. 5.

Levels of neuroectodermal gene mRNAs resulting from differentiation of marmoset iPS cells via protocol #2. For each gene, the tables list the mRNA levels as measured by qPCR for various chemical/factor combination in each of three rounds. The values in the tables are given as $C_t(\beta\text{-actin}) - C_t(\text{gene})$. The numeric code is explained in the text and is shown in Table 1. The day 0 (d0) mRNA levels, in the undifferentiated cells, are plotted as open squares. The mRNA levels in the cells at 6 days are plotted as open circles, both for the starting combination in each round and for the “winner” combination for that round. For round 1, the open circles show the mRNA levels for the 3333 combination and the “winner” combination, 3343; for round 2, levels for 3343 and the “winner” combination, 2343; for round 3, levels for 2343 and the “winner” combination, 2344.

Table 1

Small molecule/factor combinations
Concentrations of small molecules/protein factors used in two neuroectodermal differentiation protocols for marmoset iPS cells.

Protocol #1					
	RA (μM)	SB (μM)	DM (μM)	FGF (ng/ml)	SAG (μM)
1	0.001	0.1	0.1	2	0.1
2	0.01	0.32	0.32	6.3	0.32
3	0.1	1	1	20	1
4	1	3.2	3.2	63	3.2
5	10	10	10	100	10

Protocol #2				
	DMH1 (μM)	SB (μM)	BIO (μM)	PD (μM)
1	0.05	1	0.2	0.1
2	0.16	3.2	0.63	0.32
3	0.5	10	2	1
4	1.6	32	6.3	3.2
5	5	100	20	10

RA = all-*trans* retinoic acid; SB = SB431542; DM = dorsomorphin HCl; FGF = FGF2; SAG = Sonic hedgehog agonist; DMH1 = dorsomorphin analogue; BIO = (2',Z,3'E)-6-bromoindirubin-3'-oxime; PD = PD0325901. The first column (1 through 5) shows the code used for the specific concentrations of the chemicals. For example, "33333" in protocol #1 refers to the combination of 0.1 μM RA, 1 μM SB, 1 μM DM, 20 ng/ml FGF, and 1 μM SAG.